Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study

Background: Rimegepant, a small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonist, is approved for the acute and preventive treatment of migraine. We hypothesized that intermittent CGRP receptor blockade with rimegepant 75 mg acute treatment as needed (PRN) might result in red...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gilbert L'Italien (Egilea), Evan Popoff (Egilea), Karissa Johnston (Egilea), Donnie McGrath (Egilea), Charles M Conway (Egilea), Lauren Powell (Egilea), Linda Harris (Egilea), Nicole Kowalczyk (Egilea), Robert Croop (Egilea), Vladimir Coric (Egilea)
Formatua: Liburua
Argitaratua: SAGE Publishing, 2022-01-01T00:00:00Z.
Gaiak:
Sarrera elektronikoa:Connect to this object online.
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

Connect to this object online.

3rd Floor Main Library

Aleari buruzko argibideak 3rd Floor Main Library
Sailkapena: A1234.567
Alea 1 Eskuragarri